2024-11-14 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report 

**1. Performance Comparison:**

Pfizer Inc. (PFE) is a pharmaceutical company that develops and manufactures medicines and vaccines. 

**Cumulative Returns:**
* **PFE:** 8.86%
* **S&P 500 (VOO):** 179.47%

**Performance Gap:**

* **Current Gap:** -170.61%
* **Relative Gap:** 1.01 (This indicates that PFE's performance is currently in the 1st percentile compared to the S&P 500, indicating a significant underperformance).

**Alpha & Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 28.9% | 17.4% | -9.5% | 0.8 | 194.7 |
| 2016-2018  | 52.6% | 17.4% | 20.3% | 0.8 | 234.7 |
| 2017-2019  | 32.5% | 21.8% | -19.2% | 0.8 | 210.7 |
| 2018-2020  | 19.0% | 31.4% | -28.3% | 0.7 | 208.6 |
| 2019-2021  | 61.4% | 31.4% | -38.6% | 0.6 | 334.6 |
| 2020-2022  | 54.1% | 28.6% | 30.5% | 0.6 | 290.4 |
| 2021-2023  | -12.3% | 47.0% | -47.2% | 0.4 | 163.2 |
| 2022-2024  | -46.0% | 44.6% | -76.4% | 0.5 | 148.4 |

* PFE has consistently shown a lower Beta than the market, indicating a lower volatility than the S&P 500.
* PFE has experienced periods of both positive and negative alpha, highlighting its ability to sometimes outperform the market and sometimes underperform. 

**2. Recent Price Movements:**

* **Closing Price:** $26.72
* **5-day Moving Average:** $26.58
* **20-day Moving Average:** $27.70
* **60-day Moving Average:** $28.35

PFE is currently trading below its 5-day, 20-day, and 60-day moving averages, suggesting a short-term downtrend. 

**3. Technical Indicators:**

* **RSI:** 32.0 (Indicates the stock is oversold)
* **PPO:** -0.54 (Indicates bearish sentiment)
* **Delta_Previous_Relative_Divergence:** -0.39 (-) (Indicates a short-term downward trend)
* **Expected Return:** 0.0% (This is a long-term expected return based on the historical data and does not necessarily reflect the short-term outlook.)

**4. Recent Earnings & Outlook:**

| Date       | EPS | Expected EPS |
|---|---|---|
| 2024-10-29 | 1.06 | 0.614 |
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |

* PFE has consistently exceeded earnings expectations in recent quarters, suggesting strong performance and potential for future growth. 
* The most recent earnings for the quarter ending October 29, 2024, show EPS of $1.06, exceeding the estimated EPS of $0.614. This indicates a positive earnings surprise. 

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter  | Revenue  | Profit Margin |
|---|---|---|
| 2024-09-30 | $17.70B | 70.27% |
| 2024-06-30 | $13.28B  | 75.16% |
| 2024-03-31 | $14.88B | 77.29% |
| 2023-12-31 | $14.25B  | 46.92% |
| 2023-09-30 | $13.49B  | 31.30% |

* PFE has been consistently generating strong revenue and profit margin, highlighting its strong financial performance.
* The company experienced a slight dip in profit margin in the last two quarters, but this may be a result of seasonal factors and the ongoing challenges in the healthcare market. 

**2) Capital and Profitability:**

| Quarter  | Equity    | ROE |
|---|---|---|
| 2024-09-30 | $92.29B  | 4.84% |
| 2024-06-30 | $87.70B  | 0.05% |
| 2024-03-31 | $92.28B  | 3.38% |
| 2023-12-31 | $89.01B | -3.78% |
| 2023-09-30 | $96.93B | -2.46% | 

* PFE exhibits a solid capital position with a high equity value.
* The ROE has fluctuated in recent quarters but remains positive, suggesting that the company is effectively using its equity to generate profits.

**6. News & Recent Issues:**

* Please provide the specific date for which you want the news and recent issues analyzed. I need the date to search for relevant information from reliable sources like Shacknews, FINBOLD, and others.
* I can also provide insights about analyst opinions and performance highlights. 

**7. Overall Analysis:**

PFE is a large pharmaceutical company with a strong financial position and consistent revenue generation. However, its recent stock performance has lagged significantly behind the S&P 500. This underperformance is likely due to factors like the competitive nature of the pharmaceutical industry and the ongoing challenges in the healthcare market. 

Despite its current underperformance, PFE's strong earnings performance and consistent revenue generation indicate potential for future growth. The company's focus on developing innovative medicines and vaccines, coupled with its strong financial foundation, provides a solid base for potential future success. 

**Investment Recommendation:**

Considering the current market conditions and PFE's historical performance, investors should consider a long-term investment approach with a focus on value investing. 

**Important Note:** This analysis should not be considered as financial advice.  Investors should consult with a qualified financial advisor before making any investment decisions. 
